

## Disclosures

### Personal Commercial (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Janssen Pharmaceuticals, Inc	Speaker's Bureau	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Merck & Co., Inc.	Speaker's Bureau	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Merit Medical	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
<i>Spouse/Domestic Partner/Immediate Household Member</i>			
Astra Zeneca	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Other</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (5)

Trial Name	Trial Sponsor	Trial Funding Source
ABI-009, an mTOR inhibitor, for Patients with Severe Pulmonary Hypertension	Aadi Bioscience	
STELLAR	acceleron	
SOTERIA	acceleron	
Impack of CardiolRx on Myocardial Recovery in Acute Myocarditis	CardiolRx	
EXPEDITE	United Therapeutics	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/2/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/2/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 10/2/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 10/2/2025

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.